Alzheimer’s disease and immunotherapy
Abstract Alzheimer's disease (AD) is the leading cause of dementia, characterized by neuropathological features such as amyloid-β (Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration. Immunotherapy offers a promising potentially disease-modifying treatment for AD. We review recent advances in AD immunotherapy, specifically focusing on Aβ, tau, and neuroinflammation-targeted approaches, and gain insights from randomized controlled trials to propose disease-modifying directions.
Authors
- Jianping Jia (ORCID: https://orcid.org/0000-0003-4624-0336)
- Wei Qin (ORCID: https://orcid.org/0000-0003-0710-8236)
- Meina Quan (ORCID: https://orcid.org/0000-0002-6143-0798)
- Shuya Nie
- Yana Pang
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Capital Medical University (CN)
- Beijing Geriatric Hospital (CN)
- Chinese Institute for Brain Research (CN)
Publication Details
- Journal
- Current Medicine
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1007/s44194-024-00035-8
- Citations
- 10
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- National Natural Science Foundation of China
- National Key Scientific Instrument and Equipment Development Projects of China